Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Timelines...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(62)
•••
Post by WalkOverTheStrton Aug 12, 2021 1:08pm
220 Views
Post# 33694642

Timelines...

Timelines...Otenal's patent life is until 2032 (US exclusivity lost). Based off slide 20 in corp presenation.

That stated how much of a window will Otenal have (and it's attractiveness to partners) when a PH2 is added and obviosuly PH3 is delayed. Mgmt hasn't been the most speedy at trials (pre covid) so based off today's discussion what is the earliest they could complete a PH3 and gain approval if all goes exceedingly well?

Did this just set back the entire potetntial timeline 18-24 months? 
How soon could they actually get approval for a PH2, run it and have results? By end of 2022, with PH3 starting sometime in likely late 2023? 

Part of me thinks they should push 352 and reformulate Otenal so they can extend the patents as IMO partnerships are on ice for another 12-18 months. 


https://secureservercdn.net/72.167.241.46/ln9.cea.myftpupload.com/wp-content/uploads/2021/07/Antibe-Corporate-Presentation-July-2021.pdf
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities